Boardroom Alpha
Boardroom Alpha
VRTX · Additional Proxy Materials (DEFA14A) · Filed April 29, 2026

Vertex Pharmaceuticals Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 29, 2026
Ticker
VRTX
Accession
0000875320-26-000167
Boardroom Alpha · Filing insights

Vertex withdraws Suketu Upadhyay from nomination; board to shrink to ten directors; proxies remain valid for other nominees.

About Vertex Pharmaceuticals Inc
Market cap
$107.9B
1Y TSR
−2.6%
3Y TSR
+8.6%
Board grade
B-
Sector
Healthcare
CEO
Reshma Kewalramani
Last annual meeting: May 13, 2026 · View full Vertex Pharmaceuticals Inc profile →
Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
x    Filed by the Registrant                     o Filed by a Party other than the Registrant
Check the appropriate box:
o
Preliminary Proxy Statement
o
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive Proxy Statement
x
Definitive Additional Materials
o
Soliciting Material under §240.14a-12

a435534-1_vertexxlogoa.jpg
Vertex Pharmaceuticals Incorporated

(Name of Registrant as Specified In Its Charter)


Payment of Filing Fee (Check all boxes that apply):
x
No fee required.
o
Fee paid previously with preliminary materials.
o
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.




SUPPLEMENT TO THE PROXY STATEMENT OF VERTEX PHARMACEUTICALS INCORPORATED FILED APRIL 2, 2026 FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 13, 2026

The following information relates to the proxy statement (the “Proxy Statement”) of Vertex Pharmaceuticals Incorporated (the “Company”), filed April 2, 2026, and furnished to shareholders of the Company in connection with the solicitation of proxies by the board of directors of the Company (the “Board”) for the 2026 annual meeting of shareholders to be held on May 13, 2026 at 9:00 a.m. Eastern Time, and any adjournment or postponement thereof (the “2026 Annual Meeting”). This supplement to the Proxy Statement describes recent changes in the proposed nominees for election to the Board and should be read in conjunction with the Proxy Statement. Other than as described in this supplement, the information provided in the Proxy Statement remains unchanged and should be considered in voting your shares.

Withdrawal of Nominee for Election as Director

On April 28, 2026, Suketu Upadhyay informed the Board of his decision not to stand for re-election as a director of the Company at the 2026 Annual Meeting. Mr. Upadhyay has recently been named the forthcoming Chief Financial Officer of Incyte Corporation. Mr. Upadhyay will continue to serve on the Board until the time of the 2026 Annual Meeting. Mr. Upadhyay’s decision to depart from the Board was due to scheduling conflicts associated with his new role at Incyte Corporation and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

The Board intends to reduce the size of the Board to ten members following the departure of Mr. Upadhyay.

Mr. Upadhyay had been included as a nominee of the Board in the Company’s definitive proxy statement and proxy card for the 2026 Annual Meeting. In light of his anticipated departure from the Board, Mr. Upadhyay is no longer standing for re-election to the Board at the 2026 Annual Meeting, and the Company’s proxy materials are hereby deemed amended to remove Mr. Upadhyay as a nominee for the 2026 Annual Meeting. The Company’s slate of nominees otherwise remains unchanged. Previously voted proxies remain valid, other than with respect to Mr. Upadhyay as he is no longer standing for re-election, and the Company’s shareholders eligible to vote at the 2026 Annual Meeting may continue to use their proxy cards to vote their shares as to the Board’s remaining nominees and the other matters being voted on at the 2026 Annual Meeting.

Voting Matters

If you have already returned your proxy or provided voting instructions, you do not need to take any action unless you wish to change your vote. Proxies already returned by shareholders will remain valid and will be voted at the 2026 Annual Meeting unless revoked. Proxies received in respect of the re-election of Mr. Upadhyay will not be voted with respect to his election but will continue to be voted as directed or otherwise as set forth therein and described in the Proxy Statement with respect to all other matters properly brought before the 2026 Annual Meeting. If you have not yet returned your proxy card or submitted your voting instructions, please complete the card or submit instructions disregarding Mr. Upadhyay’s name as a nominee for election as director. Information regarding how to vote your shares, or revoke your proxy or voting instructions, is available in the Proxy Statement.

Sincerely,
Joy Liu
Executive Vice President, Chief Legal Officer and Secretary

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Vertex Pharmaceuticals Inc (VRTX)

Reference

Frequently asked questions

When did Vertex Pharmaceuticals Inc file this DEFA14A?
Vertex Pharmaceuticals Inc (VRTX) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 29, 2026. The accession number assigned by EDGAR is 0000875320-26-000167.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Vertex withdraws Suketu Upadhyay from nomination; board to shrink to ten directors; proxies remain valid for other nominees. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Vertex Pharmaceuticals Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Vertex Pharmaceuticals Inc has filed under CIK 875320, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer